MMP9 is involved in glycation end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline.
To determine the role of matrix metalloproteinase 9 (MMP9) in advanced glycation end-products (AGEs) induced damage to blood-retinal barrier (BRB) and the therapeutic effects of minocycline, an MMP inhibitor, against the BRB damages. Forty-eight Sprague Dawley rats were randomly assigned to 3 groups (16/group): A control group treated with bovine serum albumin (BSA), an AGE-BSA treated group, and a group treated with minocycline after AGE-BSA treatment. The retinas of all the animals were collected 2 weeks after treatment, and the levels of MMP9 protein and mRNA were detected by Western blotting, immunohistochemistry, and semi-quantitative RT-PCR. The permeability of retinal vessels was bio-assayed using the Evans Blue method. The correlation between the vessel permeability and the MMP9 protein levels was analyzed. Compared with the BSA control group, the expression of retinal MMP9 mRNA and protein were significantly increased in the AGE-BSA group, and the retinal vascular permeability was also increased in the AGE-BSA group. After the minocycline treatment, the MMP9 expression was decreased sharply and the abnormal vascular permeability was improved. There was a significant correlation between the MMP9 expression and retinal vascular permeability. MMP9 is involved in the AGE-induced retinal damage of vascular permeability, and the abnormal permeability can be partially reversed by treatment with minocycline.